About Vaxxas
Vaxxas is a company based in Sydney (Australia) founded in 2010.. Vaxxas has raised $108.48 million across 9 funding rounds from investors including Gates Foundation, HHS and Government of Australia. Vaxxas offers products and services including HD-MAP Technology. Vaxxas operates in a competitive market with competitors including Valeritas, scPharmaceuticals, Sirnaomics, Crossject and Arcturus Therapeutics, among others.
- Headquarter Sydney, Australia
-
Sectors
TechnologyHealthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Vaxxas, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$108.48 M (USD)
in 9 rounds
-
Latest Funding Round
$49.22 M (USD), Series D
Aug 25, 2025
-
Investors
Gates Foundation
& 10 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Vaxxas
Vaxxas offers a comprehensive portfolio of products and services, including HD-MAP Technology. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Provides needle-free vaccine delivery via skin microprojections for enhanced immune response.
Unlock access to complete
Unlock access to complete
Funding Insights of Vaxxas
Vaxxas has successfully raised a total of $108.48M across 9 strategic funding rounds. The most recent funding activity was a Series D round of $49.22 million completed in August 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 9
- Last Round Series D — $49.2M
-
First Round
First Round
(02 Aug 2011)
- Investors Count 11
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug, 2025 | Amount | Debt – Conventional - Vaxxas | Valuation |
investors |
|
| Aug, 2025 | Amount | Series D - Vaxxas | Valuation | SPRIM Global Investments | |
| Dec, 2022 | Amount | Series C - Vaxxas | Valuation | One Ventures , UniQuest |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Vaxxas
Vaxxas has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include Gates Foundation, HHS and Government of Australia. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm offering growth equity and credit for technology and healthcare companies.
|
Founded Year | Domain | Location | |
|
UniQuest is engaged in commercialising intellectual property and innovation.
|
Founded Year | Domain | Location | |
|
Seed & Early stage Life-Sciences focused VC Firm investing primarily in Australia
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Vaxxas
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Vaxxas
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Vaxxas Comparisons
Competitors of Vaxxas
Vaxxas operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Valeritas, scPharmaceuticals, Sirnaomics, Crossject and Arcturus Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Wearable insulin patch pumps are developed for transdermal delivery.
|
|
| domain | founded_year | HQ Location |
Provider of a device for subcutaneous drug delivery for the treatment of bacterial infections and heart failure
|
|
| domain | founded_year | HQ Location |
RNA-based therapeutics for cancer and fibrosis are developed.
|
|
| domain | founded_year | HQ Location |
Needle-free self-injectable drugs
|
|
| domain | founded_year | HQ Location |
RNAi technologies are developed for treating rare orphan diseases.
|
|
| domain | founded_year | HQ Location |
Wearable insulin delivery patches are developed for mealtime dosing.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Vaxxas
Frequently Asked Questions about Vaxxas
When was Vaxxas founded?
Vaxxas was founded in 2010 and raised its 1st funding round 1 year after it was founded.
Where is Vaxxas located?
Vaxxas is headquartered in Sydney, Australia. It is registered at Sydney, New South Wales, Australia.
Is Vaxxas a funded company?
Vaxxas is a funded company, having raised a total of $108.48M across 9 funding rounds to date. The company's 1st funding round was a Series C of $23M, raised on Aug 02, 2011.
What does Vaxxas do?
Vaxxas was founded in 2010 in Sydney, Australia, within the biotechnology sector. Vaccines targeting cancer and infectious diseases are developed through a proprietary HD-MAP platform, which enables small-patch delivery. Immune responses are enhanced, and thermostability is achieved for applications in oncology and infectious disease prevention. Operations focus on initial vaccine advancements for global health needs.
Who are the top competitors of Vaxxas?
Vaxxas's top competitors include scPharmaceuticals, Sirnaomics and Arcturus Therapeutics.
What products or services does Vaxxas offer?
Vaxxas offers HD-MAP Technology.
Who are Vaxxas's investors?
Vaxxas has 11 investors. Key investors include Gates Foundation, HHS, Government of Australia, OneVentures, and UniQuest.